AP
HZNP

AHL Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

AHL Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-106,405
Closed -$1.35M – 1425
2017
Q3 		$1.35M Buy
106,405
+70,393
+195% +$895K 0.02% 789
2017
Q2 		$427K Buy
36,012
+18,183
+102% +$226K 0.01% 960
2017
Q1 		$263K Sell
17,829
-41,944
-70% -$679K 0.01% 1104
2016
Q4 		$967K Buy
+59,773
New +$1.08M 0.03% 670
2016
Q1 		– Sell
-46,321
Closed -$1M – 867
2015
Q4 		$1M Buy
+46,321
New +$902K 0.08% 362

Other funds holding HZNP

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AHL Partners's HZNP Position: Q4 2017 in Review

AHL Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2017, closing a stake of 106,405 shares — an estimated $1.35M sold.

AHL Partners first reported a position in HZNP in Q4 2015 and held it in 5 quarters. The position peaked at $1.35M in Q3 2017. 183 funds tracked by Wall St. Rank hold HZNP as of Q4 2017.

  • AHL Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 106,405 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2017, an estimated $1.35M.
  • AHL Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 5 quarters.
  • AHL Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.35M in Q3 2017.
  • 183 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.